Search
forLearn
5 / 801 resultslearn APISCALP™
learn Selenium AAC
learn Ceramide AG
learn Selenium sulfide
Research
5 / 93 resultsresearch Multifunctional NIR‐Triggered Nanozyme‐Based Microneedles for Synergistic Eradication of MRSA and Enhanced Wound Healing
The microneedles effectively kill MRSA and improve wound healing.
research Culture Strategy Determines the Differentiation Status of Sweat Gland Cells
3D culture better preserves sweat gland cell identity than 2D culture.
research GPR39 marks specific cells within the sebaceous gland and contributes to skin wound healing
GPR39 is linked to certain cells in the sebaceous gland and helps with skin healing.
research Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)
Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
research Cell-Free Therapies: The Use of Cell Extracts to Mitigate Irradiation-Injured Salivary Glands
Cell extracts may effectively and safely repair radiation-damaged salivary glands.
Community Join
5 / 1000+ resultscommunity 32M, 5 year progress pictures
The user has been using finasteride, ketoconazole shampoo, oral minoxidil, and minoxidil foam for hair loss but feels their hair is not as thick as desired. They have stopped using RU58841 due to lack of results and are concerned about hair miniaturization despite these treatments.
community 32M, 5 year progress on Fin, Min, RU58841 and Ketoconazole 2%
A 32-year-old male shares his 5-year progress using finasteride, minoxidil, RU58841, and ketoconazole for hair loss. Despite consistent use, he feels his hair isn't as thick as before and is concerned about continued shedding and hairline miniaturization.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community GT20029 - Stand-alone Saviour or just part of the stack?
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.